Our experience with the IT-IC in situ vaccine regimen led us to test whether an unrelated CpG+OX40 in situ vaccine would be similarly ineffective as IT-IC when administered to immunologically “cold” tumor models, and whether RT could enable a response to this regimen in these models. Here, TNFRSF4 is linked to neoplasm.